Last reviewed · How we verify

Xadago — Competitive Intelligence Brief

Xadago (SAFINAMIDE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoamine Oxidase Type B Inhibitor. Area: Oncology.

marketed Monoamine Oxidase Type B Inhibitor Amine oxidase [flavin-containing] B Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Xadago (SAFINAMIDE) — Mdd Us. Xadago works by blocking the enzyme amine oxidase [flavin-containing] B, which breaks down dopamine in the brain.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Xadago TARGET SAFINAMIDE Mdd Us marketed Monoamine Oxidase Type B Inhibitor Amine oxidase [flavin-containing] B 2017-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoamine Oxidase Type B Inhibitor class)

  1. Mdd Us · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xadago — Competitive Intelligence Brief. https://druglandscape.com/ci/safinamide. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: